Is there a future for prenyltransferase inhibitors in cancer therapy?

Sarah A. Holstein, Raymond Hohl

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

It has been over 20 years since it was first recognized that the function of both normal and oncogenic Ras is dependent on the post-translational modification termed farnesylation. Since that time, intense effort has been expended on the development of farnesyltransferase inhibitors as novel anticancer agents. Over 70 clinical trials have now been conducted, with limited efficacy demonstrated. Here we provide an update of the most recently published clinical trials, discuss the use of the RASGRP1/APTX two-gene expression screen to select patients with acute myeloid leukemia for therapy, and report on the latest discoveries related to the targets of prenyltransferase inhibitors.

Original languageEnglish (US)
Pages (from-to)704-709
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume12
Issue number6
DOIs
StatePublished - Jan 1 2012

Fingerprint

Dimethylallyltranstransferase
Clinical Trials
Farnesyltranstransferase
Prenylation
Post Translational Protein Processing
Acute Myeloid Leukemia
Antineoplastic Agents
Neoplasms
Gene Expression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

@article{1495b26de4a34ba78c822b8c54419d8b,
title = "Is there a future for prenyltransferase inhibitors in cancer therapy?",
abstract = "It has been over 20 years since it was first recognized that the function of both normal and oncogenic Ras is dependent on the post-translational modification termed farnesylation. Since that time, intense effort has been expended on the development of farnesyltransferase inhibitors as novel anticancer agents. Over 70 clinical trials have now been conducted, with limited efficacy demonstrated. Here we provide an update of the most recently published clinical trials, discuss the use of the RASGRP1/APTX two-gene expression screen to select patients with acute myeloid leukemia for therapy, and report on the latest discoveries related to the targets of prenyltransferase inhibitors.",
author = "Holstein, {Sarah A.} and Raymond Hohl",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.coph.2012.06.013",
language = "English (US)",
volume = "12",
pages = "704--709",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "6",

}

Is there a future for prenyltransferase inhibitors in cancer therapy? / Holstein, Sarah A.; Hohl, Raymond.

In: Current Opinion in Pharmacology, Vol. 12, No. 6, 01.01.2012, p. 704-709.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Is there a future for prenyltransferase inhibitors in cancer therapy?

AU - Holstein, Sarah A.

AU - Hohl, Raymond

PY - 2012/1/1

Y1 - 2012/1/1

N2 - It has been over 20 years since it was first recognized that the function of both normal and oncogenic Ras is dependent on the post-translational modification termed farnesylation. Since that time, intense effort has been expended on the development of farnesyltransferase inhibitors as novel anticancer agents. Over 70 clinical trials have now been conducted, with limited efficacy demonstrated. Here we provide an update of the most recently published clinical trials, discuss the use of the RASGRP1/APTX two-gene expression screen to select patients with acute myeloid leukemia for therapy, and report on the latest discoveries related to the targets of prenyltransferase inhibitors.

AB - It has been over 20 years since it was first recognized that the function of both normal and oncogenic Ras is dependent on the post-translational modification termed farnesylation. Since that time, intense effort has been expended on the development of farnesyltransferase inhibitors as novel anticancer agents. Over 70 clinical trials have now been conducted, with limited efficacy demonstrated. Here we provide an update of the most recently published clinical trials, discuss the use of the RASGRP1/APTX two-gene expression screen to select patients with acute myeloid leukemia for therapy, and report on the latest discoveries related to the targets of prenyltransferase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84870505131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870505131&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2012.06.013

DO - 10.1016/j.coph.2012.06.013

M3 - Review article

C2 - 22817869

AN - SCOPUS:84870505131

VL - 12

SP - 704

EP - 709

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 6

ER -